Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - metformin hydrochloride + 0.5% magnesium stearate; saxagliptin hydrochloride anhydrous 5.58mg eqv saxagliptin - tablet, film coated, extended release - 1000mg - metformin hydrochloride + 0.5% magnesium stearate 1000mg; saxagliptin hydrochloride anhydrous 5.58mg eqv saxagliptin 5.0mg

Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - metformin hydrochloride + 0.5% magnesium stearate; saxagliptin hydrochloride anhydrous 5.58mg eqv saxagliptin - tablet, film coated, extended release - 500mg - metformin hydrochloride + 0.5% magnesium stearate 500mg; saxagliptin hydrochloride anhydrous 5.58mg eqv saxagliptin 5.0mg

Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - tamoxifen citrate 15.2 mg eqv tamoxifen - tablet, film coated - 10 mg - tamoxifen citrate 15.2 mg eqv tamoxifen 10 mg

Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - tamoxifen citrate 30.4mg eqv tamoxifen - tablet, film coated - 20 mg - tamoxifen citrate 30.4mg eqv tamoxifen 20 mg

Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - goserelin acetate eqv peptide - injection - 3.6 mg/syringe - goserelin acetate eqv peptide 3.6 mg/syringe

Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - saxagliptin hydrochloride (anhydrous) 2.79 mg eqv saxagliptin - tablet, film coated - 2.5 mg - saxagliptin hydrochloride (anhydrous) 2.79 mg eqv saxagliptin 2.5 mg

Singapur - Englisch - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - saxagliptin hydrochloride (anhydrous) 5.58 mg eqv saxagliptin - tablet, film coated - 5 mg - saxagliptin hydrochloride (anhydrous) 5.58 mg eqv saxagliptin 5 mg

Europäische Union - Englisch - myHealthbox

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/850 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

Europäische Union - Englisch - myHealthbox

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/1,000 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - olaparib (unii: woh1jd9ar8) (olaparib - unii:woh1jd9ar8) - olaparib 50 mg - lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline brca -mutated (gbrcam ) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. none. risk summary based on findings in animals and its mechanism of action [see clinical pharmacology (12.1)] , lynparza can cause fetal harm when administered to a pregnant woman. there are no available data on lynparza use in pregnant women to inform the drug associated risk. in an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily [see data] . apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. the estimated background risk of major birth d